Effect of remifentanil and midazolam on ED95 of propofol for loss of consciousness in elderly patients: A randomized, clinical trial by 김도형 et al.
Clinical Trial/Experimental Study Medicine®
OPENEffect of remifentanil and midazolam on ED95 of
propofol for loss of consciousness in elderly
patients
A randomized, clinical trial
Ann Hee You, MD, PhDa, Ji Young Kim, MD, PhDb,c, Do-Hyeong Kim, MD, PhDb,c, Jiwoo Suh, MDb,
Dong Woo Han, MD, PhDb,c,
∗
Abstract
Background: Older people are more vulnerable to hemodynamic instability caused by propofol due to their decreased initial
distribution volume and increased sensitivity to propofol. Midazolam or remifentanil can often be coadministered because of their
synergistic or additive effects with propofol as well as amnesic properties and the blockade of sympathetic stimulation. However, no
study has conﬁrmed the appropriate dose of propofol for loss of consciousness in aged patients when administered with other drugs,
including opioids or benzodiazepines.
Methods:Patients>65 years scheduled for general anesthesia were enrolled. The patients were randomized into 3 groups using a
computer-generated randomization table. Patients in group P (propofol) received only propofol for loss of consciousness, those in
group PR (propofol–remifentanil) received remifentanil before propofol, and those in group PMR (propofol–midazolam–remifentanil)
received remifentanil and midazolam before propofol. After propofol administration, loss of both eyelash reﬂex and verbal response
represented success. The 95% effective dose of propofol for loss of consciousness in each group, which was the primary outcome,
was determined using a modiﬁed biased coin up-and-down method.
Results: In total, 120 patients were randomized into the 3 groups (n=40). The 95% effective dose of propofol for loss of
consciousness was 1.13, 0.87, and 0.72mg/kg in groups P, PR, and PMR, respectively. The mean blood pressure (MBP) in group
PMRwasmore signiﬁcantly decreased before propofol injection (P= .041) as well as 2minutes (P= .005) and 3minutes after propofol
administration (P<.001), compared with group P, but there were no intergroup differences at other time points.
Conclusions: The effective dose of propofol for loss of consciousness in elderly patients could be decreased by 23% and 36%
when remifentanil pretreatment was used without and with midazolam, respectively. However, the decrease in MBPwas greater with
remifentanil and midazolam pretreatment than with propofol alone. These ﬁndings suggest that pretreatment with midazolam for
propofol infusions with remifentanil in elderly patients should be cautiously used, due to hemodynamic instability during induction.
Abbreviations: ED95 = 95% effective dose, HR = heart rate, MBP = mean blood pressure, PAVA = pooled adjacent violators
algorithm.
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Propofol, a hypnotic agent, can provide quick and smooth
induction when used for general anesthesia. It also has aEditor: Joho Tokumine.
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1bronchodilating effect and prevents postoperative nausea and
vomiting.[1] These advantages lead many anesthesiologists to
select propofol as an induction agent. However, it is well known
that propofol shows dose-dependent hemodynamic instability,
such as hypotension and bradycardia, during induction or bolus
administration.[2] The hemodynamic instability is due to dose-
dependent decreased systemic vascular resistance and myocardial
contractility.[3,4] In particular, in elderly patients or volume-
depleted patients, the hemodynamic instability becomes more
dramatic. Anesthesiologists, therefore, have to be cautious when
selecting the propofol dose for induction in such patients, and the
minimal dose of propofol that provides sufﬁcient sedation for
most patients has to be administered.
Some trials have been conducted tominimize the propofol dose
for the induction of hemodynamic susceptible patients. Coin-
duction with other analgesics or benzodiazepines can lead to
additive or synergistic effects and can thus reduce propofol
requirements. It can also decrease the hemodynamic change
during the induction period.[5] However, no study has conﬁrmed
the appropriate dose of propofol for loss of consciousness in aged
patients when administered with other drugs like opioids or
benzodiazepines. Therefore, we designed this study to estimate
You et al. Medicine (2019) 98:16 Medicinethe 95% effective dose (ED95) of propofol when patients are
pretreated with usual doses of remifentanil or remifentanil with
midazolam, and to investigate whether remifentanil and mid-
azolam pretreatment can reduce hemodynamic instability during
propofol induction.2. Methods
This study protocol was approved by the Institutional Review
Board of Gangnam Severance Hospital (approval no.: 3-2015-
0222) and registered at clinicaltrial.gov (NCT02818387).
Patients >65 years scheduled for general anesthesia were
considered eligible. Patients with an American Society of
Anesthesiologists physical status ≥3; who were allergic to
propofol, remifentanil, or midazolam; whose body mass index
was 20 or ≥30 (kg/m2); or who were taking hypnotics or
antianxiety agents were excluded from the study. Patient who
could not read or write or who could not understand the
procedure or the consent procedure were also excluded. Written
informed consent was obtained from all participants.2.1. Study protocol
In total, 120 patients were enrolled and divided into 3 groups
using a computer-generated randomization table. Before the
transfer to the operation room, a 20-gauge intravenous catheter
was inserted at the patient’s basilic vein and 5mL/kg of lactated
Ringer’s solution was infused before the induction. Intravenous
glycopyrrolate (0.1mg) was administered as premedication to all
patients. In the operating room, the monitoring included pulse
oximetry, noninvasive blood pressure, an electrocardiogram, and
mult-gas analysis. Each patient received intravenous propofol
after 5 minutes of preoxygenation. After the monitoring, group P
(propofol) was induced only with propofol. In group PR
(propofol–remifentanil), 0.125mg/kg/min of remifentanil was
continuously infused from the start of preoxygenation until 3
minutes after propofol administration. In group PMR (propofol–
midazolam–remifentanil), intravenous midazolam 0.025mg/kg
was additionally administered 1 minute after preoxygenation.
Due to concerns about increased brain sensitivity and decreased
drug clearance in elderly patients, the initial propofol dose was
determined to be 0.5mg/kg, and the doses of remifentanil and
midazolam were half of the doses reported in a prior study by
Koh et al that was performed in healthy young patients.[6,7] After
the predetermined dose of propofol was administered, the loss of
the eyelash reﬂex and verbal response was assessed for 3 minutes.
Induction success was represented by loss of both the eyelash
reﬂex and verbal response. All other cases were considered
failures.Table 1
Demographic characteristics of the patients in each group.
P (n=40) PR
Age, y 72.3±4.86 7
Height, cm 157.5±8.50 159
Weight, kg 60.55±8.63 61
Comorbidities
Hypertension 22 (55%) 23
Diabetes mellitus 7 (17.5%) 6
Values are mean± standard deviation or the patient number (percentage). Group P: patients who received o
before propofol. Group PMR: patients who received both midazolam (0.025mg/kg) and remifentanil bef
2The dose of propofol was determined before the induction
according to the up-and-down method using a biased coin design
which was described by Durham et al.[6,8] If induction failed in
one patient, the propofol dose for the next patient was increased
by 0.125mg/kg. If induction was successful in one patient, the
dose for the next patient was determined with a randomly
selected card from a total of 19 cards. With a probability of 1/19,
the dose for the next patient was decreased by 0.125mg/kg, and
the same dose was administered with a probability of 18/19.
Mean blood pressure (MBP), heart rate (HR), and oxygen
saturation were measured at baseline, immediately before
propofol injection, and 1, 2, and 3 minutes after propofol
injection. Any adverse effects were monitored and recorded.2.2. Statistical analysis
A minimum of 40 subjects were required, according to the
methods of Durham et al.[7] We therefore enrolled 40 patients in
each group. Statistical analyses were performed using the
Statistical Package for Social Sciences (ver. 20.0 for Windows;
SPSS Inc., Chicago, IL) and R for Windows (R ver. 3.2.0). The
pooled adjacent violators algorithm (PAVA) was used to predict
the effective dose of propofol for the successful loss of
consciousness in 95% of patients (ED95), and bootstrapping
was used to estimate the 95% conﬁdence intervals. ANOVA and
a linear mixed model were used to analyze the demographic data
and hemodynamic changes in each group. A P < .05 was
considered statistically signiﬁcant.3. Results
From the total of 126 patients, 6 refused to participate in the
study. A total of 120 patients were equally divided into 3 groups.
No demographic differences in age, height, weight, and
comorbidity (Table 1) were observed. Figure 1 depicts the
allocation sequence for each group according to the biased coin
design. Starting from propofol 0.5mg/kg, the propofol dose for
the next patient was increased by 0.125mg/kg if the induction
was failed. If induction was successful, the dose for the next
patient was decreased by 0.125mg/kg with a probability of 1/19,
and the same dose was administered with a probability of 18/19.
The pooled adjacent violators algorithm-adjusted success rate in
each group is shown in Figure 2. The dose required for loss of
consciousness during induction was higher in group P, followed
in group PR and then group PMR. The ED95 of propofol for loss
of consciousness was 1.13, 0.87, and 0.72mg/kg in groups P, PR,
and PMR, respectively (Table 2).
Figure 3 shows the hemodynamic proﬁles. In all groups, the




(57.5%) 20 (50%) .791
(15%) 8 (20%) .841
nly propofol for loss of consciousness. Group PR: patients who received remifentanil (0.125mg/kg/min)
ore propofol.
Figure 1. Assessment of success or failure of anesthesia induction by a predetermined bolus dose of propofol determined for consecutive patients using a
modiﬁed biased coin design in each group. Induction success (loss of consciousness) is indicated by solid circles, and induction failure (no loss of consciousness) is
indicated by open circles. Group P: patients who received only propofol for loss of consciousness. Group PR: patients who received remifentanil (0.125mg/kg/min)
before propofol. Group PMR: patients who received both midazolam (0.025mg/kg) and remifentanil before propofol.
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Figure 2. The pooled adjacent violators algorithm (PAVA)-adjusted success rate according to dose level in each group. Group P: patients who received only
propofol for loss of consciousness. Group PR: patients who received remifentanil (0.125mg/kg/min) before propofol. Group PMR: patients who received both
midazolam (0.025mg/kg) and remifentanil before propofol.
You et al. Medicine (2019) 98:16 Medicinepropofol administration, compared with baseline (P<.001 for all
groups at each time). However, the MBP was also decreased
before propofol administration in group PR (P= .001) and group
PMR (P<.001), respectively. TheMBP in group PMR, compared
with Group P, was signiﬁcantly decreased before propofol
injection (P= .041) as well as 2 minutes (P= .005) and 3 minutes
after propofol administration (P<.001), but there were no
intergroup differences at other time points.
In all groups, the HR was signiﬁcantly decreased 1 minute
(P= .045 in group P, P<.001 in groups PR and PMR), 2 minutes
(P= .001 in group P, P<.001 in groups PR and PMR), and 3
minutes (P<.001 in all groups) after propofol administration,
comparedwith baseline. Before propofol administration, only the
HR in group PMR showed a signiﬁcant decrease compared with
baseline (P= .001). However, there were no intergroup differ-
ences in HR at any time points. No adverse effects related to the
administered drugs were recorded.4. Discussion
In this study, we investigated the ED95 of propofol with no
pretreatment (group P), remifentanil pretreatment (group PR),
and remifentanil plus midazolam pretreatment (group PMR) in
elderly patients for loss of consciousness during the induction of
general anesthesia. Our results show that the required dose of
propofol was reduced to 22.4% with using remifentanil, and
35.8% with remifentanil with midazolam. However, the MBPTable 2
Comparison of the 95% effective dose (ED95) of propofol for loss of
consciousness using isotonic regression in each group.
P (n=40) PR (n=40) PMR (n=40)
ED95, mg/kg 1.13 (1.11–1.24) 0.87 (0.86–0.98) 0.72 (0.7–0.73)
Values are means (95% conﬁdence intervals). Group P: patients who received only propofol for loss of
consciousness. Group PR: patients who received remifentanil (0.125mg/kg/min) before propofol.
Group PMR: patients who received both midazolam (0.025mg/kg) and remifentanil before propofol.
ED95=95% effective dose.
4decreased signiﬁcantly after pretreatment with remifentanil and
midazolam, compared with the group that received only
propofol.
Nowadays, elderly patients constitute a large proportion of the
surgical population. Anesthesiologists are often faced with the
need for tailoring anesthesia techniques, to account for geriatric
physiology. Unfortunately, geriatric-speciﬁc guidelines on anes-
thesia do not exist, and an anesthesiologist may thus try to
modify techniques based on a nonscientiﬁc impression of what is
best for the patient. Furthermore, it has been reported that elderly
patients commonly receive greater-than-recommended doses (1–
1.5mg/kg) of propofol for the induction of general anesthesia.[9]
In our result, the ED95 of propofol for loss of consciousness in
elderly patients (>65 years) was 1.13mg/kg, which is 35% lower
than that reported for 20- to 50-year-old patients (1.74mg/kg) in
a previous study.[7] Our ﬁndings are similar to those of Olmos
et al, showing a 37% reduction in the effect-site concentration of
propofol for hypnosis in patients>60 years compared with those
<40 years.[10] Our results conﬁrm the guideline for minimal
administration of propofol, as higher doses can be unnecessarily
excessive in elderly patients. Older people are more vulnerable to
hemodynamic instability caused by propofol, due to a decreased
initial distribution volume and increased sensitivity to propo-
fol.[9,11,12] It has been reported that postinduction hypotension
was associated with increased mortality, and that intraoperative
hypotension caused reinfarction in 20% of patients with
myocardial infarction.[13,14] Concerns about hemodynamic
depression in old patients lead anesthesiologists to avoid using
propofol alone for induction and to use combinations with other
drugs. In addition, midazolam and remifentanil are often
required during the induction period because of their strong
amnesic property and the blockade of sympathetic stimulation
induced by laryngoscopy and intubation. Synergistic effects of
propofol and opioids, benzodiazepines, or both have been
reported.[10,15–18] However, we are not aware of recommenda-
tions regarding the appropriate dose of propofol during
induction when opioids or benzodiazepines are coadministered
in elderly patients. Opioids are also commonly used with
Figure 3. Mean blood pressure and heart rate values at baseline, before propofol administration, and 1, 2, and 3 minutes after propofol administration in each
group. Values are presented as the mean±standard deviation. MBP=mean blood pressure, HR=heart rate, Baseline= the patient is at rest, 0min=before
injection of designated dose of propofol, 1, 2, and 3minutes=1, 2, and 3 minutes after propofol injection, Group P: patients who received only propofol for loss of
consciousness. Group PR: patients who received remifentanil (0.125mg/kg/min) before propofol. Group PMR: patients who received both midazolam (0.025mg/
kg) and remifentanil before propofol. xSigniﬁcantly decreased compared with groups P and PMR (P<.05), ¤ signiﬁcantly decreased compared with groups P and
PMR (P<.01). ∗Signiﬁcantly decreased compared with groups P and PMR (P<.001). ^Signiﬁcantly decreased compared with baseline (P<.05). †Signiﬁcantly
decreased compared with baseline (P<.01). ‡Signiﬁcantly decreased compared with baseline (P<.001).
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You et al. Medicine (2019) 98:16 Medicinepropofol for the induction of general anesthesia because propofol
does not have an analgesic effect. Opioids can help anesthesi-
ologists reduce the propofol dose because they lead to synergistic
effects in hypnosis.[19] However, compared with the synergistic
effects of propofol and benzodiazepines, the synergism between
propofol and opioids has been reported to be rather weak [16,20]
and the hypnotic synergism between propofol and opiates shows
a ceiling effect.[15] With remifentanil pretreatment, the ED95 of
propofol (0.87mg/kg) was reduced by 23%, in comparison to
propofol alone (1.13mg/kg), in our results. The reduction of the
dose of propofol after pretreatment with remifentanil in elderly
patients is comparable to that reported for young patients (21%
dose reduction of propofol).[7] We cannot estimate the exact drug
interaction of propofol and remifentanil because an isobolo-
graphic analysis was not conducted in our study. However, our
results suggest that propofol doses ≥1.0mg/kg are more than
necessary for loss of consciousness in the elderly (>65 years)
when remifentanil pretreatment is coadministered during the
induction period.
Midazolam is a frequently selected benzodiazepine because of
its short half-life, pH-dependent solubility, and short elimination
half-life.[21,22] Midazolam has a great advantage in eliminating
unpleasant perioperative memories because of its strong antero-
grade amnesic properties. Furthermore, in addition to its
anxiolytic effect, intravenous preadministration of midazolam
has been reported to reduce postoperative nausea and vomiting
and increase patient satisfaction.[23] We expected coinduction
with midazolam and remifentanil to lead to better hemodynamic
stability because of a higher reduction of the propofol dose
resulting from synergistic or additive effects of midazolam and
propofol, comparedwith propofol alone. However, the reduction
of the propofol requirement for hypnosis in elderly patients after
pretreatment with midazolam and remifentanil might be smaller
than what we had expected. The exact mechanism is not well
understood; however, Vinik et al found that the propofol–
midazolam–alfentanil interaction resulted in profound hypnotic
synergism that was, however, not signiﬁcantly different from that
of the binary propofol–alfentanil combination.[17,20] This implies
that the 3-drug combination did not produce as much sedation as
expected from the combined doses of the individual agents and
the pairwise interactions.[20] Pretreatment with midazolam and
remifentanil led to a signiﬁcant decrease in MBP, compared with
propofol alone, possibly caused by the midazolam-induced
alteration of propofol pharmacokinetics. When combined with
midazolam, propofol concentrations reach higher levels than
when propofol is administered alone.[24] Although we did not
measure propofol concentrations and do not know the propofol
pharmacokinetics, it seems that pretreatment with midazolam
does not reduce propofol requirements enough to cause more
stable blood pressure in the elderly. Our results suggest that
during induction with propofol with remifentanil pretreatment in
elderly patients, prior administration of midazolam should
be carefully considered because it may lead to worsen
hemodynamic instability.
Bradycardia is commonly caused by opioids,[25,26] presumably
because of vagal or chronotropic effects. In the PMR group, the
HR decreased even before propofol administration, whereas it
did not decrease until propofol was administered in groups P and
PR. In addition, the PR and PMR groups showed a higher
tendency toward a decrease in HR than the group P, although
there was no signiﬁcant difference in HR at any time point
between the groups. It may be advisable to be careful with
midazolam or remifentanil pretreatment in older patients with6marked or severe bradycardia or hemodynamic instability, even if
most elderly patients have no problem.
This study has several limitations. First, we did not analyze
hemodynamic parameters during the postinduction period
because the study was not designed for this purpose; additional
doses of propofol administered to the patients were declared as
“failure.” Moreover, we used an inhalation agent after loss of
consciousness to obtain deeper analgesia for endotracheal
intubation. Second, although patients with an American Society
of Anesthesiologists physical status ≥4 were excluded, elderly
patients with comorbidities, such as hypertension or diabetes,
were heterogeneously included, which might have resulted in
variations in hemodynamic responses to the drugs during the
study period.
In conclusion, the effective dose of propofol for loss of
consciousness in elderly patients could be decreased by 23% and
36%when remifentanil pretreatment was used without and with
midazolam, respectively. However, the decrease in blood
pressure was greater with remifentanil and midazolam pretreat-
ment than with propofol alone. These ﬁndings suggest that
pretreatment with midazolam should be cautiously used because
of the hemodynamic instability during induction with propofol
with remifentanil infusion in elderly patients.Acknowledgments
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